What’s Driving bioAffinity Technologies’ Big Pre-Market Surge?

All NewsOctober 8, 2025

bioAffinity Technologies shares surged over 20% pre-market following a strong third-quarter sales update for its lung cancer diagnostic test.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent